Complement and the hemostatic system: An intimate relationship

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Weitz, Ilene Ceil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Complement; PNH; Thrombosis; TMA

Indexed keywords

BETA2 GLYCOPROTEIN 1; CD40 LIGAND; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; D DIMER; DECAY ACCELERATING FACTOR; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MESSENGER RNA; SELECTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UROKINASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN ISCHEMIA; CAVERNOUS SINUS THROMBOSIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DEEP VEIN THROMBOSIS; GAIN OF FUNCTION MUTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOSTASIS; HUMAN; INTRAVASCULAR HEMOLYSIS; LUNG EMBOLISM; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; IMMUNOLOGY; NEOPLASM; THROMBOSIS;

COMPLEMENT SYSTEM PROTEINS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYTIC-UREMIC SYNDROME; HEMOSTASIS; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 84901470324     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50020-5     Document Type: Article

References (74)

1. I.C. Weitz Thrombosis in Paroxysmal Nocturnal Hemoglobinuria Semin Thromb Hemost 37 2011 315 321
2. S. Vlaicu, C.A. Tegla, C. Cudrici, J. Danoff, H. Madani, and A. Sugarman et al. Role of C5b-9 complement complex and responsive gene to complement-32 (RCG-32) in cancer Immunol Research 56 2013 109 121
3. P.F. Zipfel, T. Hallstrom, and K. Riesbeck Human Complement Control and complement evasion by pathogenic microbes- Tipping the balance Molecular Immunology 56 2013 152 160
4. K. Riis, M. Doumas, and D. Mastello A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways J Immuno 177 2006 4794 4802 (Pubitemid 44469814)
5. M.J. Krisinger, V. Goebeler, Z. Lu, S.C. Meixner, T. Myles, E.L. Pryzdial, and E.M. Conway Thrombin generates previously unidentified C5 products that support terminal complement activation Blood 120 2012 1717 1725
6. A. Landsem, E.W. Neilsen, H. Fure, D. Christiansen, J.K. Ludviksen, and J.D. Lambris et al. C1q inhibitor efficiently inhibits Eschericia Coli- induced tissue factor mRNA upregulation and monocyte tissue Factor expression and coagulation in human whole blood Clin Exp Immunol 173 2013 217 229
7. J. Takeda, T. Miyata, K. Kawagoe, Y. Iida, Y. Endo, and T. Fujita et al. Deficiency of the GPI anchor caused by a 5somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria Cell 73 1993 703 711 (Pubitemid 23159009)
8. J.W. Lee, J.H. Jang, J.J.S. Kim, S.S. Yoon, J.H. Lee, and Y.K. Kim et al. Clinical signs and symptoms associated with increased risk of thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry Int J Hematol 97 2013 749 755
9. X.F. Le, T.Y. Yang, X.Y. Yang, and W.M. Wang Characteristics of paroxysmal nocturnal hemoglobinuria I China. Clinical analysis of 476 cases China Med J 103 1990 885 889
10. J. Nishimura, Y. Kanakura, R.E. Ware, T. Shichishima, H. Nakakuma, and H. Ninomiya et al. Clinical course and flow cytometric analysios of paroxysmal nocturnal hemoglobinuria in the United States and Japan Medicine (Baltimore) 83 2004 193 207 (Pubitemid 38649949)
11. R.H. White, and C.R. Keenan Effects of race and ethnicity on the incidence of venous thromboembolism Thrombosis Res 123 suppl4 2009 S11 7
12. R.P. de Latour, J.Y. Mary, C. Salanoubat, L. Terriou, G. Etienne, and M. Mohty et al. Paroxysmal Nocturnal Hemoglobinuria: Natural History of disease subcategories Blood 112 2008 3099 3106
13. P. Hillmen, S.M. Lewis, M. Bessler, L. Luzzato, and J.V. Dacie Natural History of paroxysmal nocturnal hemoglobinuria NEJM 333 1995 1253 1258
14. P. Hillmen, P. Muss, U. Duhrsen, A.M. Risitano, J. Schubert, and L. Luzzatto et al. Effect of the complement inhibitor Eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Blood 110 2007 4123 4128 (Pubitemid 350248472)
15. M. Gostyninski, S. Engelter, S. Papa, V. Ajdaci-Gross, F. Gutzwiller, and P. Lyrer Incidence of first ischemic stroke in the Canton Basle-City Switzerland: A population based study. 2002-2003 J Neurol 25 2006 86 91 (Pubitemid 43157393)
16. B. Hugel, G. Socie, T. Vu, F. Toti, E. Gluckman, and J.M. Freyssinet et al. Elevated circulating microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia Blood 93 1999 3451 3456 (Pubitemid 29220912)
17. P. Muss, A.M. Risitano, H.R. Castro-Malaspina, C.M. Jones, S. Fuller, and G. Socie Clinical Impact of Unregulated Terminal Complement Activity in Never- Transfused Patients with Paroxysmal Nocturnal Hemoglobinuria Blood (ASH Annual Meeting Abstracts) 114 2009 4029
18. A.M. Almeida, Y. Murakami, A. Baker, Y. Maeder, I.A. Roberts, and T. Kinoshita et al. Targeted therapy for inherited GPI deficiency NEJM 356 2007 1641 1647 (Pubitemid 46631673)
19. I.C. Weitz, P. Razavi, L. Rochanda, J. Zwicker, B. Furie, and D. Manly et al. Eculizumab results in rapid and sustained decrease in markers of thrombin generation and inflammation in patients with PNH independent of its effect on hemolysis and microparticles Thromb Res 130 2012 361 368
20. J. Lawrence Atypical Hemolytic Uremic Syndrome (aHUS): Making the diagnosis Clin Adv Hematol Oncol 10 Suppl 17 2012 1 12
21. V.M. Moyo, G.L. Mukhina, E.S. Garrett, and R.A. Brodsky Natural History of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays BJH 126 2004 133 138 (Pubitemid 38859494)
22. K. Riis, M. Doumas, and D. Mastello A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways J Immuno 177 2006 4794 4802 (Pubitemid 44469814)
23. P. Redecha, R. Tilley, M. Tencati, J.E. Salmon, D. Kirchofer, and N. Mackman et al. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury Blood 110 2007 2423 2431 (Pubitemid 47523163)
24. J.L. Zwicker, H.A. Liebman, D. Neuberg, R. Lacroix, K.A. Bauer, and B.C. Furie et al. Tumor derived tissue factor bearing microparticles are associated with venous thromboembolic events in malignancy Clin Cancer Res 15 2009 6830 6840
25. H.A. Liebman, and D.I. Feinstein Thrombosis in patients with paroxysmal nocturnal hemoglobin is associated with markedly elevated plasma levels of leukocyte derived tissue factor Thromb Res 111 4-5 2003 235 238 (Pubitemid 38021941)
26. M. Davila, A. Amirkhosrani, E. Coll, H. Desai, L. Robles, and J. Colon Tissue factor bearing microparticles derived from tumor cell: impact on coagulation activation J Thromb Haemost 6 2008 1517 1524
27. I. Del Conde, L.D. Bharwani, D.J. Dietzen, U. Pendurthi, P. Thiagarajan, and J.A. Lopez Microvesicle-associated tissue factor and Trousseau's syndrome J Thromb Haemost 5 2007 70 74 (Pubitemid 44921069)
28. T. Weidmer, S.E. Hall, T.L. Ortel, W.H. Kane, W.F. Rosse, and P.J. Sims Complement -induced vesiculation and exposure of prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria Blood 82 1993 1192 1196 (Pubitemid 23253993)
29. H. Lowes, E. Vellenga, and J.T.M. de Wolf Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria Ann Hemeatol 80 2001 573 576 (Pubitemid 33061996)
30. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 198;391:591-4.
31. J. Simak, K. Holada, A.M. Risitano, J.H. Zivny, N.S. Young, and J.G. Vostal Elevated circulating endothelial microparticles in paroxysmal nocturnal hemoglobinuria BJH 125 2004 804 813 (Pubitemid 38813608)
32. D. Helley, R.P. de Latour, R. Porcher, C.A. Rodrigues, I. Galy-Fauroux, and J. Matheron et al. Evaluation of hemostasis and endothelial cell function in patients with paroxysmal nocturnal hemoglobinuria Haematologica 95 2010 574 584
33. S.A. Maroney, and A.E. Mast Expression of tissue factor pathway inhibitor endothelial cells and platelets Transfus Apher Sci 38 2008 9 14
34. R.A. Ariens, G. Alberio, M. Moia, and P.M. Manucci Low levels of heparin releasable tissue factor pathway inhibitor in young patients with thrombosis Thromb Haemost 819 1999 203 207 (Pubitemid 29078303)
35. M. Grunewald, A. Siegemund, A. Grunewald, A. Schmid, M. Koksch, and C. Schopflin et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size Blood Coagul Fibrinolysis 14 2003 685 695 (Pubitemid 37323748)
36. P. Hillmen, P. Muus, U. Duhrsen, A.M. Risitano, J. Schubert, and L. Luzzatto et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Blood 110 2007 4123 4128 (Pubitemid 350248472)
37. J. Laurence Atypical Hemolytic Uremic Syndome (aHUS): Making the Diagnosis Clin Adv Hematol Oncol 10 Suppl 17 2012 3 9
38. B. Renner, J. Klawitter, R. Goldberg, J.W. McCullough, and V.P. Ferreira et al. Cyclosporin induces endothelial damage releasing complement activating microparticles JASN 24 2013 1849 1862
39. J.A. Blake-Haskins, R.J. Lechleider, and R.J. Kreitman Thrombotic Microangiopathy with targeted cancer agents Clin Cancer Res 17 2011 5858 5866
40. F. Lansigan, I. Isufi, and C.E. Tagoe Microangiopahic haemolytic anemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosis: role of ADAMTS13 Rheumatology 50 2011 824 829
41. S. Jodele, C. Licht, J. Goebel, B.P. Dixon, K. Zhang, and T.A. Sivakumaran et al. Abnormalities the Alternative Pathway of Complement in Children with hematopoetic stem cell transplantation associated thrombotic microangiopathy Blood 122 2013 2003 2007
42. M. Noris, and G. Remuzzi Atypical Hemolytic Uremic Syndrome NEJM 361 2009 1676 1687
43. S.T. Test, and V.S. Woolworth Defective regulation of Complement by Sickle Erythrocytes: Evidence for defective Control of the Membrane Attack Complex formation Blood 83 1994 842 852 (Pubitemid 24043748)
44. M. Frimat, F. Tabarin, J.D. Dimitrov, C. Poitou, L. Halbwachs-Mecarelli, and V. Fremeaux-Bacchi et al. Complement activation by heme as a secondary hit for atypical hemolytic ureic syndrome Blood 12 2013 282 292
45. C.M. Legendre, C. Licht, P. Muss, L.A. Greenbaum, S. Babu, and C. Bedrosian et al. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome NEJM 368 2013 2169 2181
46. S. Jondele, T. Fukuda, A. Vinks, K. Mizuno, and B. Laskin et al. Eculizumab Therapy in Children with Bone Marrow Transplant associated TMA Biol Blood Marrow Transplant 20 2014 518 525
47. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle A, Ogawa M, et al. Biomarkers of Complement Activation Inflammation Endothelial Activation and Damage, Thrombosis and Renal injury in Patients with Atypical Hemolytic Uremia Syndrome (aHUS) prior to and during treatment with Eculizumab. Blood 2013 abstr 2184.
48. F.A.B. Anderson, R.J. Goldberg, D.W. Hormer, and A. Forcier A population-based perspective of hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism Arch Intern Med 151 1991 93
49. S. Goldhaber Thrombosis and Thromboembolism, Venous Thromboembolism: Clinical Impact and Multifactorial Etiology 2002 Marcel Dekker, Inc New York 211 224
50. M. Turiel, P. Sarzi-Puttini, R. Peretti, E. Rossi, F. Atzeni, and W. Parsons et al. Thrombotic risk factors in primary antiphospholipid syndrome. A 5-year prospective study Stroke 36 2005 1490 1494 (Pubitemid 40967518)
51. M. Mahler, G.L. Norman, P.L. Meroni, and M. Khashtman Autoantibodies to the domain 1 of Beta-2glycoprotein 1: A promising biomarker for risk management in the antiphospholipid syndrome Autoimmun Rev 12 2012 313 317
52. I. Krause, L. Leibovici, M. Blank, and Y. Shoenfeld Clusters of Disease Manifestations in patients with the antiphospholipidsyndrome by factor analysis Lupus 16 2007 176 180 (Pubitemid 46506594)
53. E. Zuckerman, E. Toubi, T.D. Golan, and T. Rosenvald-Zuckerman Increased thromboembolic incidence in anti-cardiolipin psotive patients with malignancy BJ Cancer 72 1995 447 451
54. K.H. Yoon, A. Wong, T. Shakespeare, and P. Sivalingen High prevelance of Antiphospholipid Antibodies in Asian Cancer patients with Thrombosis Lupus 12 2003 112 116 (Pubitemid 36240844)
55. S. Pusterla, S. Prevatali, S. Marziali, S. Cortelazzo, A. Rossi, and T. Barbui et al. Antiphospholipid Antibodies in Lymphoma: prevalence and clinical significance Hematol J 5 2004 341 346 (Pubitemid 39214212)
56. P. Thiagarajan, S.S. Shapiro, and L. De Marco Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant J Clin Invest 66 1980 397 405 (Pubitemid 10053902)
57. I. Krause, L. Leibovici, M. Blank, and Y. Shoenfeld Management of thrombosis in women with antiphopholipis syndrome Clinical Obstet Gynecol 44 2001 36 47
58. P.L. Meroni, N. Del Papa, E. Raschi, P. Panzeri, M.O. Borghi, and A. Tincani et al. Beta-2-glycoprotein I as a "cofactor" for anti-phospholipid reactivity with endothelial cells Lupus 7 suppl 2 1998 S44
59. A. Arad, V. Proulle, R.A. Furie, B.C. Furie, and B. Furie Beta-2-glycoprotein-1 autoantibodies are sufficient to potentiate arterial thrombosis in the antiphospholipid syndrome in the mouse model Blood 117 2011 3453 3459
60. B. Giannakopoulous Krilis SA The pathogenesis of the antiphopholipid syndrome NEJM 368 2013 1033 1044
61. A. Bontadi, A. Ruffatti, E. Falcinelli, S. Gianninni, and A. Marturano et al. Platelet and Endothelial cell activation in catastrophic and quiescent antiphospholipid syndrome Thromb Haemost 109 2013 921 928
62. S.S. Pierangeli, G. Girardi, M. Vega-Ostertag, X. Liu, R.G. Espinola, and J. Salmon Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia Arthritis Rheum 52 2005 2120 2124 (Pubitemid 40994335)
63. S.K. Bowry, and T.H. Rintelen Synthetically modified cellulose (SMC): A cellulosic hemodialysis membrane with minimized complement activation ASAIO J 44 1998 579 583
64. R.A. Asherson, R. Cervera, J.T. Merrill, and D. Erkan Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment Semin Thromb Hemost 34 2008 256 266
65. G. Espinosa, S. Bucciarelli, R.A. Asherson, and R. Cervera Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors Semin Thromb Hemost 34 2008 290 294
66. R. Cervera, J.C. Piette, J. Font, M.A. Khamashta, Y. Shoenfeld, and M.T. Camps et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Arthritis Rheum 46 2002 1019 1027 (Pubitemid 34303815)
67. M. Tincari, M. Taroborelli, and R. Cattaneo Antiphospholipid antibodies and Malignancies Autoimmun Rev 9 2010 200 202
68. R. Simantov, J.M. LaSala, S.K. Lo, A.E. Gharavi, L.R. Sammaritano, and J.E. Salmon et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies J Clin Invest 96 1995 2211 2219
69. G. Girardi, P. Redecha, and J.E. Salmon Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation Nat Med 10 2004 1222 1226 (Pubitemid 39540439)
70. I. Shapira, D. Andrade, S.L. Allen, and J.E. Salmon Induction of Sustained Remission in Recurrent Catosastrophic antiphospholipid syndrome via Inhibition of Terminal Complement with Eculizumab Arthritis Rheum 64 2012 2719 2723
71. Y. Ishida, K. Yamashita, H. Sasaki, I. Tokajou, Y. Kubuki, and K. Morishita et al. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: A serum proteomic approach using mass spectrometry Cancer Lett 271 2008 167 177
72. L. Bjorge, J. Hakulinen, O.K. Vintermyr, H. Jarva, T.S. Jensen, and O.E. Iversen et al. Ascitic complement system in ovarian cancer Br J Cancer 92 2005 895 905 (Pubitemid 40462637)
73. N.J. Scolding, B.P. Morgan, W.A. Houston, C. Linington, A.K. Campbell, and D.A. Compston Vesicular removal by oligodenrocytes of membrane attack complexes formed by activated complement Nature 339 1989 620 622
74. M. Fosbrink, C. Cudrici, C.A. Tegla, K. Soloviova, T. Ito, and S. Vlaicu et al. Response gene to Complement 32 induced cell cycle activation in endothelial cells Exp Mol Path 86 2009 87 94